Tryptophan hydroxylase as novel target for the treatment of depressive disorders

Pharmacology

Volumn 85, Issue 2, 2010, Pages 95-109

  Matthes, Susann ^a   Mosienko, Valentina ^a   Bashammakh, Saleh ^a   Alenina, Natalia ^a   Bader, Michael ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Antidepressants; Depression; Schizophrenia; Serotonin

Indexed keywords

POLYCYCLIC AROMATIC HYDROCARBON; SEROTONIN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 2; ANTIDEPRESSANT AGENT; TPH1 PROTEIN, HUMAN; TPH2 PROTEIN, HUMAN;

DEPRESSION; DRUG TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; SEROTONIN METABOLISM; SEROTONINERGIC NERVE CELL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE; TRYPTOPHAN METABOLISM; ANIMAL; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEM; ENZYMOLOGY; GENE TARGETING; GENETICS; HUMAN; METABOLISM; MISSENSE MUTATION; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; GENE TARGETING; HUMANS; MUTATION, MISSENSE; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE;

EID: 75549091083     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000279322     Document Type: Review

References (194)

1. Rapport MM, Green AA, Page IH: Partial purification of the vasoconstrictor in beef serum. J Biol Chem 1948;174:735-741.
2. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, Mac-Lean MR: Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007;49:232-236.
3. Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock AJ, Harmar A, Bader M, MacLean MR: Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008;117:2928-2937.
4. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Graf R, Clavien PA: Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008;68:5152-5158.
5. Walther DJ, Peter JU, Winter S, Höltje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M: Serotonylation of small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell 2003;115:851-862.
6. Duerschmied D, Canault M, Lievens D, Brill A, Cifuni SM, Bader M, Wagner DD: Serotonin stimulates platelet receptor shedding by tumor necrosis factor-α-converting enzyme (ADAM17). J Thromb Haemost 2009; 7:1163-1171.
7. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA: Platelet-derived serotonin mediates liver regeneration. Science 2006;312:104-107.
8. Nocito A, Georgiev P, Dahm F, Jochum W, Bader M, Graf R, Clavien PA: Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology 2007;45:369-376.
9. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA: Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007;133:608-618.
10. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, Cervantes-Barragan L, Ludewig B, Calzascia T, Bolinger B, Merkler D, Odermatt B, Bader M, Graf R, Clavien PA, Hegazy AN, Lohning M, Harris NL, Ohashi PS, Hengartner H, Zinkernagel RM, Lang KS: Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 2008; 14:756-761.
11. Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry M, Bailey JP, Nieport KM, Walther DJ, Bader M, Horseman ND: Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev Cell 2004;6:193-203.
12. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, Skelin M, Jevsek M, Fink H, Rupnik M, Walther DJ: Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol 2009;7:e1000229.
13. Gaspar P, Cases O, Maroteaux L: The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003; 4:1002-1012.
14. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229.
15. Lucki I: The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998; 44: 151-162.
16. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr: Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000;410:165-181.
17. Fitzpatrick PF: Tetrahydropterin-dependent amino acid hydroxylases. Annu Rev Biochem 1999;68:355-381.
18. Flatmark T, Stevens RC: Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem Rev 1999;99:2137-2160.
19. Walther DJ, Bader M: A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003;66:1673-1680.
20. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M: Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76.
21. Patel PD, Pontrello C, Burke S: Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biol Psychiatry 2004;55:428-433.
22. Gutknecht L, Waider J, Kraft S, Kriegebaum C, Holtmann B, Reif A, Schmitt A, Lesch KP: Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice. J Neural Transm 2008;115:1127-1132.
23. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vodjdani G: Disruption of the nonneuronal Tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA 2003;100: 13525-13530.
24. Neal KB, Parry LJ, Bornstein JC: Strain-specific genetics, anatomy and function of enteric neural serotonergic pathways in inbred mice. J Physiol 2009;587:567-586.
25. Zill P, Buttner A, Eisenmenger W, Bondy B, Ackenheil M: Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains. Eur Neuropsychopharmacol 2004; 14:282-284.
26. Sakowski SA, Geddes TJ, Thomas DM, Levi E, Hatfield JS, Kuhn DM: Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res 2006;1085:11-18.
27. Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, Slominski RM, Tobin DJ: On the role of melatonin in skin physiology and pathology. Endocrine 2005;27:137-148.
28. Lesch KP: Gene-environment interaction and the genetics of depression. J Psychiatry Neurosci 2004;29:174-184.
29. Ruhe HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 2007;12:331-359.
30. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-919.
31. Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC: Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004;61:765-773.
32. Mann JJ, Malone KM: Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 1997; 41:162-171.
33. Asberg M: Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann NY Acad Sci 1997;836: 158-181.
34. Russo S, Kema IP, Bosker F, Haavik J, Korf J: Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications. World J Biol Psychiatry 2007;1-11.
35. Gainetdinov RR, Caron MG: Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 2003;43:261-284.
36. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-295.
37. Ressler KJ, Nemeroff CB: Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety dis orders. Depress Anxiety 2000; 12(suppl 1):2-19.
38. Hornung JP: The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003;26:331-343.
39. Fava M, Kendler KS: Major depressive disorder. Neuron 2000;28:335-341.
40. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627.
41. Wurtman RJ: Genes, stress, and depression. Metabolism 2005;54:16-19.
42. Utge S, Soronen P, Partonen T, Loukola A, Kronholm E, Pirkola S, Nyman E, Porkka-Heiskanen T, Paunio T: A population-based association study of candidate genes for depression and sleep disturbance. Am J Med Genet B Neuropsychiatr Genet 2009 Jun 22. Epub ahead of print.
43. Toney SD: Identifying and managing depression in women. J Manag Care Pharm 2007;13:S16-S22.
44. Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, Schwartz DA, Krishnan KR, Caron MG: Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005;45:11-16.
45. Zill P, Baghai TC, Zwanzger P, Schule C, Eser D, Rupprecht R, Moller HJ, Bondy B, Ackenheil M: SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004;9: 1030-1036.
46. Zhou Z, Roy A, Lipsky R, Kuchipudi K, Zhu G, Taubman J, Enoch MA, Virkkunen M, Goldman D: Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 2005;62:1109-1118.
47. Haghighi F, Bach-Mizrachi H, Huang YY, Arango V, Shi S, Dwork AJ, Rosoklija G, Sheng HT, Morozova I, Ju J, Russo JJ, Mann JJ: Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression. Mol Psychiatry 2008;13:813-820.
48. Van Den Bogaert A, Sleegers K, De Zutter S, Heyrman L, Norrback KF, Adolfsson R, Van Broeckhoven C, Del-Favero J: Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. Arch Gen Psychiatry 2006;63:1103-1110.
49. Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ, Hou SJ, Yen FC: Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:637-641.
50. Cichon S, Winge I, Mattheisen M, Georgi A, Karpushova A, Freudenberg J, Freudenberg-Hua Y, Babadjanova G, Van Den Bogaert A, Abramova LI, Kapiletti S, Knappskog PM, McKinney J, Maier W, Jamra RA, Schulze TG, Schumacher J, Propping P, Rietschel M, Haavik J, Nothen MM: Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5′-region are associated with bipolar affective disorder. Hum Mol Genet 2008;17:87-97.
51. Harvey M, Gagne B, Labbe M, Barden N: Polymorphisms in the neuronal isoform of tryptophan hydroxylase 2 are associated with bipolar disorder in French Canadian pedigrees. Psychiatr Genet 2007;17:17-22.
52. Harvey M, Shink E, Tremblay M, Gagne B, Raymond C, Labbe M, Walther DJ, Bader M, Barden N: Support for the involvement of TPH2 gene in affective disorders. Mol Psychiatry 2004;9:980-981.
53. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ: Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. Biol Psychiatry 2007;61: 181-186.
54. Roche S, McKeon P: Support for tryptophan hydroxylase-2 as a susceptibility gene for bipolar affective disorder. Psychiatr Genet 2009;19:142-146.
55. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M: Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry 2004;56:581-586.
56. Lin YM, Chao SC, Chen TM, Lai TJ, Chen JS, Sun HS: Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Arch Gen Psychiatry 2007;64: 1015-1024.
57. Gizatullin R, Zaboli G, Jonsson EG, Asberg M, Leopardi R: The tryptophan hydroxylase (TPH) 2 gene unlike TPH1 exhibits no association with stress-induced depression. J Affect Disord 2008;107:175-179.
58. De Luca V, Mueller DJ, Tharmalingam S, King N, Kennedy JL: Analysis of the novel Tph2 gene in bipolar disorder and suicidality. Mol Psychiatry 2004;9:896-897.
59. Mouri K, Hishimoto A, Fukutake M, Shiroiwa K, Asano M, Nagasaki Y, Ueno Y, Shirakawa O, Nishiguchi N, Maeda K: TPH2 is not a susceptibility gene for suicide in Japanese population. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1546-1550.
60. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O: 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009;20: 1125-1128.
61. Mann JJ, Currier D, Murphy L, Huang YY, Galfalvy H, Brent D, Greenhill L, Oquendo M: No association between a TPH2 promoter polymorphism and mood disorders or monoamine turnover. J Affect Disord 2008; 106:117-121.
62. Garriock HA, Allen JJ, Delgado P, Nahaz Z, Kling MA, Carpenter L, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA: Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005;10:976-977.
63. Tenner K, Walther D, Bader M: Influence of human tryptophan hydroxylase 2 N- and C-terminus on enzymatic activity and oligomerization. J Neurochem 2007;102:1887-1894.
64. Zhang X, Beaulieu JM, Gainetdinov RR, Caron MG: Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci 2006;63:6-11.
65. Van Den Bogaert A, De Zutter S, Heyrman L, Mendlewicz J, Adolfsson R, Van Broeckhoven C, Del-Favero J: Response to Zhang et al (2005): Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005;48:704; author reply 705-706.
66. Zhou Z, Peters EJ, Hamilton SP, McMahon F, Thomas C, McGrath PJ, Rush J, Trivedi MH, Charney DS, Roy A, Wisniewski S, Lipsky R, Goldman D: Response to Zhang et al. (2005): Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005;48:702-703; author reply 705-706.
67. Bicalho MA, Pimenta GJ, Neves FS, Correa H, de Moraes EN, De Marco L, Romano-Silva MA: Genotyping of the G1463A (Arg441His) TPH2 polymorphism in a geriatric population of patients with major depression. Mol Psychiatry 2006;11:799-800.
68. Blakely RD: Overview: a rare opportunity or just one less reason to be depressed. Neuron 2005;48:701-702; author reply 705-706.
69. Delorme R, Durand CM, Betancur C, Wagner M, Ruhrmann S, Grabe HJ, Nygren G, Gillberg C, Leboyer M, Bourgeron T, Courtet P, Jollant F, Buresi C, Aubry JM, Baud P, Bondolfi G, Bertschy G, Perroud N, Malafosse A: No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. Biol Psychiatry 2006;60:202-203.
70. Glatt CE, Carlson E, Taylor TR, Risch N, Reus VI, Schaefer CA: Response to Zhang et al. (2005): Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. Neuron 2005;48:704-705; author reply 705-706.
71. Henningsson S, Annerbrink K, Olsson M, Allgulander C, Andersch S, Sjodin I, Gustafson D, Skoog I, Eriksson E, Westberg L: Absence of the Arg441His polymorphism in the tryptophan hydroxylase 2 gene in adults with anxiety disorders and depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:816-817.
72. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, Mc-Grath PJ, Hamilton SP: Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009;19:1-10.
73. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.
74. Breidenthal SE, White DJ, Glatt CE: Identification of genetic variants in the neuronal form of tryptophan hydroxylase (TPH2). Psychiatr Genet 2004;14:69-72.
75. Reuter M, Esslinger C, Montag C, Lis S, Gallhofer B, Kirsch P: A functional variant of the tryptophan hydroxylase 2 gene impacts working memory: a genetic imaging study. Biol Psychol 2008;79:111-117.
76. Gutknecht L, Jacob C, Strobel A, Kriegebaum C, Muller J, Zeng Y, Markert C, Escher A, Wendland J, Reif A, Mossner R, Gross C, Brocke B, Lesch KP: Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. Int J Neuropsychopharmacol 2007;10:309-320.
77. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, Hariri AR: A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 2005;10:884-888, 805.
78. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP: Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 2005; 112: 1479-1485.
79. Stein DJ, Westenberg HG, Liebowitz MR: Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 2002; 63(suppl 6):12-19.
80. Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P, Heinz A, Walther DJ, Priller J: Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 2007;62:1288-1294.
81. Chen GL, Vallender EJ, Miller GM: Functional characterization of the human TPH2 5′ regulatory region: untranslated region and polymorphisms modulate gene expression in vitro. Hum Genet 2008;122:645-657.
82. McKinney JA, Turel B, Winge I, Knappskog PM, Haavik J: Functional properties of missense variants of human tryptophan hydroxylase 2. Hum Mutat 2009;30:787-794.
83. Haavik J, Blau N, Thony B: Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 2008;29:891-902.
84. Sheehan K, Lowe N, Kirley A, Mullins C, Fitzgerald M, Gill M, Hawi Z: Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 2005;10: 944-949.
85. Walitza S, Renner TJ, Dempfle A, Konrad K, Wewetzer C, Halbach A, Herpertz-Dahlmann B, Remschmidt H, Smidt J, Linder M, Flierl L, Knolker U, Friedel S, Schafer H, Gross C, Hebebrand J, Warnke A, Lesch KP: Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 2005;10:1126-1132.
86. Coon H, Dunn D, Lainhart J, Miller J, Hamil C, Battaglia A, Tancredi R, Leppert MF, Weiss R, McMahon W: Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2) . Am J Med Genet B Neuropsychiatr Genet 2005;135B:42-46.
87. Mossner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, Bogusch L, Remschmidt H, Simons M, Herpertz-Dahlmann B, Fleischhaker C, Schulz E, Warnke A, Hinney A, Wewetzer C, Lesch KP: Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2006;9:437-442.
88. Kim YK, Lee HJ, Yang JC, Hwang JA, Yoon HK: A tryptophan hydroxylase 2 gene polymorphism is associated with panic disorder. Behav Genet 2009;39:170-175.
89. De Luca V, Voineskos D, Wong GW, Shinkai T, Rothe C, Strauss J, Kennedy JL: Promoter polymorphism of second tryptophan hydroxylase isoform (TPH2) in schizophrenia and suicidality. Psychiatry Res 2005;134: 195-198.
90. Mossner R, Freitag CM, Gutknecht L, Reif A, Tauber R, Franke P, Fritze J, Wagner G, Peikert G, Wenda B, Sand P, Rietschel M, Garritsen H, Jacob C, Lesch KP, Deckert J: The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. J Psychopharmacol 2006;20:547-552.
91. De Luca V, Hlousek D, Likhodi O, Van Tol HH, Kennedy JL, Wong AH: The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses. Genes Brain Behav 2006;5:107-110.
92. O'Reilly RL, Bogue L, Singh SM: Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994;36:467-471.
93. Franchini L, Serretti A, Gasperini M, Smeraldi E: Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998;32:255-259.
94. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.
95. Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J: Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 2008; 18:495-506.
96. Liu X, Li H, Qin W, He G, Li D, Shen Y, Shen J, Gu N, Feng G, He L: Association of TPH1 with suicidal behaviour and psychiatric disorders in the Chinese population. J Med Genet 2006;43:e4.
97. Mann JJ, Malone KM, Nielsen DA, Goldman D, Erdos J, Gelernter J: Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am J Psychiatry 1997;154:1451-1453.
98. Rujescu D, Giegling I, Sato T, Hartmann AM, Moller HJ: Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatry 2003;54:465-473.
99. Bellivier F, Chaste P, Malafosse A: Association between the TPH gene A218C polymorphism and suicidal behavior: a metaana lysis. Am J Med Genet B Neuropsychiatr Genet 2004;124B:87-91.
100. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D, Linnoila M: A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998;55:593-602.
101. Jokela M, Raikkonen K, Lehtimaki T, Rontu R, Keltikangas-Jarvinen L: Tryptophan hydroxylase 1 gene (TPH1) moderates the influence of social support on depressive symptoms in adults. J Affect Disord 2007; 100:191-197.
102. Sun HS, Tsai HW, Ko HC, Chang FM, Yeh TL: Association of tryptophan hydroxylase gene polymorphism with depression, anxiety and comorbid depression and anxiety in a population-based sample of postpartum Taiwanese women. Genes Brain Behav 2004;3:328-336.
103. Gizatullin R, Zaboli G, Jonsson EG, Asberg M, Leopardi R: Haplotype analysis reveals tryptophan hydroxylase (TPH) 1 gene variants associated with major depression. Biol Psychiatry 2006;59:295-300.
104. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse A: Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry 1998;55:33-37.
105. Chen C, Glatt SJ, Tsuang MT: The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. Bipolar Disord 2008;10:816-821.
106. Zaboli G, Gizatullin R, Nilsonne A, Wilczek A, Jonsson EG, Ahnemark E, Asberg M, Leopardi R: Tryptophan hydroxylase-1 gene variants associate with a group of suicidal borderline women. Neuropsychopharmacology 2006;31:1982-1990.
107. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E: Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001;6:586-592.
108. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E: Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001;11:375-380.
109. Ham BJ, Lee BC, Paik JW, Kang RH, Choi MJ, Choi IG, Lee MS: Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:104-107.
110. Lalovic A, Turecki G: Meta-analysis of the association between tryptophan hydroxylase and suicidal behavior. Am J Med Genet 2002;114:533-540.
111. Yoon HK, Kim YK: Association between serotonin-related gene polymorphisms and suicidal behavior in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1293-1297.
112. Viana MM, De Marco LA, Boson WL, Romano-Silva MA, Correa H: Investigation of A218C tryptophan hydroxylase polymorphism: association with familial suicide behavior and proband's suicide attempt characteristics. Genes Brain Behav 2006;5: 340-345.
113. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC: No association of the tryptophan hydroxylase gene with bipolar affective disorder, unipolar affective disorder, or suicidal behaviour in major affective disorder. Am J Med Genet 1998;81: 245-247.
114. Stefulj J, Kubat M, Balija M, Skavic J, Jernej B: Variability of the tryptophan hydroxylase gene: study in victims of violent suicide. Psychiatry Res 2005;134:67-73.
115. Ham BJ, Lee MS, Lee HJ, Kang RH, Han CS, Choi MJ, Lee SH, Ryu SH: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005;15: 299-301.
116. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1279-1283.
117. Du L, Faludi G, Palkovits M, Bakish D, Hrdina PD: Tryptophan hydroxylase gene 218A/C polymorphism is not associated with depressed suicide. Int J Neuropsychopharmacol 2000;3:215-220.
118. Souery D, Van Gestel S, Massat I, Blairy S, Adolfsson R, Blackwood D, Del-Favero J, Dikeos D, Jakovljevic M, Kaneva R, Lattuada E, Lerer B, Lilli R, Milanova V, Muir W, Nothen M, Oruc L, Papadimitriou G, Propping P, Schulze T, Serretti A, Shapira B, Smeraldi E, Stefanis C, Thomson M, Van Broeckhoven C, Mendlewicz J: Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biol Psychiatry 2001;49:405-409.
119. Tsai SJ, Hong CJ, Wang YC: Tryptophan hydroxylase gene polymorphism (A218C) and suicidal behaviors. Neuroreport 1999; 10:3773-3775.
120. Kato M, Wakeno M, Okugawa G, Fukuda T, Azuma J, Kinoshita T, Serretti A: No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007;56: 167-171.
121. Coon SL, Mazuruk K, Bernard M, Roseboom PH, Klein DC, Rodriguez IR: The human serotonin N-acetyltransferase (EC 2.3.1.87) gene (AANAT) : structure, chromosomal localization, and tissue expression. Genomics 1996;34:76-84.
122. Holmes A: Genetic variation in corticoamygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 2008;32:1293-1314.
123. Nakamura K, Sugawara Y, Sawabe K, Ohashi A, Tsurui H, Xiu Y, Ohtsuji M, Lin QS, Nishimura H, Hasegawa H, Hirose S: Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci 2006;26:530-534.
124. Nakamura K, Hasegawa H: Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol 2007;35:45-54.
125. Gutknecht L, Kriegebaum C, Waider J, Schmitt A, Lesch KP: Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: convergent data from Tph2 knockout mice. Eur Neuropsychopharmacol 2009;19:266-282.
126. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.
127. Hasler G, Drevets WC, Manji HK, Charney DS: Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29:1765-1781.
128. Cryan JF, Holmes A: The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005;4: 775-790.
129. Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005;29:571-625.
130. Invernizzi RW: Role of TPH-2 in brain function: news from behavioral and pharmacologic studies. J Neurosci Res 2007;85: 3030-3035.
131. Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 2008;455: 894-902.
132. Renard CE, Dailly E, David DJ, Hascoet M, Bourin M: Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 2003;17:449-455.
133. Koe BK, Weissman A: p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther 1966;154:499-516.
134. Vataeva LA, Khozhai LI, Makukhina GV, Otellin VA: Behavior of female and male mice submitted to action of p-chlorophenylalanine in prenatal ontogenesis (in Russian). Zh Evol Biokhim Fiziol 2007;43:346-351.
135. Vataeva LA, Kudrin VS, Vershinina EA, Mosin VM, Tiul'kova EI, Otellin VA: Behavioral alteration in the adult rats prenatally exposed to para-chlorophenylalanine. Brain Res 2007;1169:9-16.
136. Vataeva LA, Kudrin VS, Vershinina EA, Mosin VM, Tiul'kova EI, Otellin VA: Maternal para-chlorophenylalanine exposure modifies central monoamines and behaviors in the adult offspring. Brain Res 2008; 1234:1-7.
137. Baumgarten HG, Lachenmayer L: Serotonin neurotoxins - past and present. Neurotox Res 2004;6:589-614.
138. Chia LG, Ni DR, Cheng FC, Ho YP, Kuo JS: Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice. Neurochem Res 1999; 24:719-722.
139. Hall FS, Devries AC, Fong GW, Huang S, Pert A: Effects of 5,7-dihydroxytryptamine depletion of tissue serotonin levels on extracellular serotonin in the striatum assessed with in vivo microdialysis: relationship to behavior. Synapse 1999;33:16-25.
140. Kostowski W, Krzascik P: Neonatal 5-hydroxytryptamine depletion induces depressive-like behavior in adult rats. Pol J Pharmacol 2003;55:957-963.
141. Savelieva KV, Zhao S, Pogorelov VM, Rajan I, Yang Q, Cullinan E, Lanthorn TH: Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One 2008;3:e3301.
142. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG: Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004;305:217.
143. Sakowski SA, Geddes TJ, Kuhn DM: Mouse tryptophan hydroxylase isoform 2 and the role of proline 447 in enzyme function. J Neurochem 2006;96:758-765.
144. Osipova DV, Kulikov AV, Popova NK: C1473G polymorphism in mouse tph2 gene is linked to tryptophan hydroxylase-2 activity in the brain, intermale aggression, and depressive-like behavior in the forced swim test. J Neurosci Res 2009;87:1168-1174.
145. Kulikov AV, Osipova DV, Popova NK: The C1473G polymorphism in gene tph2 is the main factor mediating the genetically defined variability of tryptophan hydroxylase-2 activity in the mouse brain (in Russian). Genetika 2007;43:1676-1681.
146. Tenner K, Qadri F, Bert B, Voigt JP, Bader M: The m TPH2 C1473G single nucleotide polymorphism is not responsible for behavioural differences between mouse strains. Neurosci Lett 2008;431:21-25.
147. Crowley JJ, Blendy JA, Lucki I: Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) 2005;183:257-264.
148. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG: Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008;105:1333-1338.
149. Alenina N, Kikic D, Todiras M, Mosienko V, Qadri F, Plehm R, Boye P, Vilianovitch L, Sohr R, Tenner K, Hortnagl H, Bader M: Growth retardation and altered autonomic control in mice lacking brain serotonin. Proc Natl Acad Sci USA 2009;106:10332-10337.
150. Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID: Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci 2005;25:6807-6815.
151. Londei T, Valentini AM, Leone VG: Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 1998;94:249-254.
152. Shedlovsky A, McDonald JD, Symula D, Dove WF: Mouse models of human phenylketonuria. Genetics 1993;134:1205-1210.
153. Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinohe A, Kojima K, Matsubara Y, Kobayahi E, Okada T, Hoshika A, Ozawa K, Kume A: Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 2004;11: 1081-1086.
154. Zagreda L, Goodman J, Druin DP, McDonald D, Diamond A: Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental
155. Cabib S, Pascucci T, Ventura R, Romano V, Puglisi-Allegra S: The behavioral profile of severe mental retardation in a genetic mouse model of phenylketonuria. Behav Genet 2003;33:301-310.
156. Pascucci T, Ventura R, Puglisi-Allegra S, Cabib S: Deficits in brain serotonin synthesis in a genetic mouse model of phenylketonuria. Neuroreport 2002;13:2561-2564.
157. Pascucci T, Andolina D, Mela IL, Conversi D, Latagliata C, Ventura R, Puglisi-Allegra S, Cabib S: 5-Hydroxytryptophan rescues serotonin response to stress in prefrontal cortex of hyperphenylalaninaemic mice. Int J Neuropsychopharmacol 2009;12: 1067-1079.
158. Coleman CM, Neckameyer WS: Serotonin synthesis by two distinct enzymes in Drosophila melanogaster. Arch Insect Biochem Physiol 2005;59:12-31.
159. Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B, Silver J, Weeber EJ, Sweatt JD, Deneris ES: Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 2003;37:233-247.
160. Lerch-Haner JK, Frierson D, Crawford LK, Beck SG, Deneris ES: Serotonergic transcriptional programming determines maternal behavior and offspring survival. Nat Neurosci 2008;11:1001-1003.
161. Zhao ZQ, Scott M, Chiechio S, Wang JS, Renner KJ, Gereau RW 4th, Johnson RL, Deneris ES, Chen ZF: Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. J Neurosci 2006;26:12781-12788.
162. Zhao ZQ, Chiechio S, Sun YG, Zhang KH, Zhao CS, Scott M, Johnson RL, Deneris ES, Renner KJ, Gereau RW 4th, Chen ZF: Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 2007;27:6045-6053.
163. Agren H, Reibring L: PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 1994;27:2-6.
164. Turner EH, Loftis JM, Blackwell AD: Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006;109:325-338.
165. Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998;3:271-280.
166. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
167. Leonard BE: New approaches to the treatment of depression. J Clin Psychiatry 1996; 57(suppl 4):26-33.
168. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR * D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
169. Turner MS, May DB, Arthur RR, Xiong GL: Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med 2007;261:205-213.
170. Reeves RR, Wise PM, Cox SK: SSRIs and the risk of abnormal bleeding. J Psychosoc Nurs Ment Health Serv 2007;45:15-21.
171. Warden SJ, Robling AG, Haney EM, Turner CH, Bliziotes MM: The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 2009 Jul 8. Epub ahead of print.
172. Perlis RH: Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am 2007;30: 125-138.
173. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC: Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008;325:47-55.
174. Jin H, Cianchetta G, Devasagayaraj A, Gu K, Marinelli B, Samala L, Scott S, Stouch T, Tunoori A, Wang Y, Zang Y, Zhang C, David Kimball S, Main AJ, Ding ZM, Sun W, Yang Q, Yu XQ, Powell DR, Wilson A, Liu Q, Shi ZC: Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg Med Chem Lett 2009;19:5229-5232.
175. McKinney J, Knappskog PM, Haavik J: Different properties of the central and peripheral forms of human tryptophan hydroxylase. J Neurochem 2005;92:311-320.
176. Windahl MS, Boesen J, Karlsen PE, Christensen HE: Expression, purification and enzymatic characterization of the catalytic domains of human tryptophan hydroxylase isoforms. Protein J 2009 Oct 9. Epub ahead of print.
177. Nakata H, Fujisawa H: Purification and properties of tryptophan 5-monooxygenase from rat brain-stem. Eur J Biochem 1982;122:41-47.
178. Nakata H, Fujisawa H: Tryptophan 5-monooxygenase from mouse mastocytoma P815. A simple purification and general properties. Eur J Biochem 1982;124:595-601.
179. McKinney J, Knappskog PM, Pereira J, Ekern T, Toska K, Kuitert BB, Levine D, Gronenborn AM, Martinez A, Haavik J: Expression and purification of human tryptophan hydroxylase from Escherichia coli and Pichia pastoris. Protein Expr Purif 2004;33:185-194.
180. Murphy KL, Zhang X, Gainetdinov RR, Beaulieu JM, Caron MG: A regulatory domain in the N terminus of tryptophan hydroxylase 2 controls enzyme expression. J Biol Chem 2008;283:13216-13224.
181. Carkaci-Salli N, Flanagan JM, Martz MK, Salli U, Walther DJ, Bader M, Vrana KE: Functional domains of human tryptophan hydroxylase 2 (hTPH1). J Biol Chem 2006; 281:28105-28112.
182. Thorolfsson M, Ibarra-Molero B, Fojan P, Petersen SB, Sanchez-Ruiz JM, Martinez A: L-Phenylalanine binding and domain organization in human phenylalanine hydroxylase: a differential scanning calo rimetry study. Biochemistry 2002;41:7573-7585.
183. Thorolfsson M, Doskeland AP, Muga A, Martinez A: The binding of tyrosine hydroxylase to negatively charged lipid bilayers involves the N-terminal region of the enzyme. FEBS Lett 2002;519:221-226.
184. Winge I, McKinney JA, Ying M, D'Santos CS, Kleppe R, Knappskog PM, Haavik J: Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem J 2008; 410:195-204.
185. Kuhn DM, Sakowski SA, Geddes TJ, Wilkerson C, Haycock JW: Phosphorylation and activation of tryptophan hydroxylase 2: identification of serine-19 as the substrate site for calcium, calmodulin-dependent protein kinase II. J Neurochem 2007; 103: 1567-1573.
186. Moy LY, Tsai LH: Cyclin-dependent kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability. J Biol Chem 2004;279:54487-54493.
187. Royo M, Fitzpatrick PF, Daubner SC: Mutation of regulatory serines of rat tyrosine hydroxylase to glutamate: effects on enzyme stability and activity. Arch Biochem Biophys 2005;434:266-274.
188. Johansen PA, Jennings I, Cotton RG, Kuhn DM: Phosphorylation and activation of tryptophan hydroxylase by exogenous protein kinase A. J Neurochem 1996;66:817-823.
189. Moran GR, Fitzpatrick PF: A continuous fluorescence assay for tryptophan hydroxylase. Anal Biochem 1999;266:148-152.
190. Walther DJ, Peter JU, Bader M: 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer 2002;94:3135-3140.
191. Ke L, Qi ZY, Ping Y, Ren CY: Effect of SNP at position 40237 in exon 7 of the TPH2 gene on susceptibility to suicide. Brain Res 2006;1122:24-26.
192. Lopez de Lara C, Brezo J, Rouleau G, Lesage A, Dumont M, Alda M, Benkelfat C, Turecki G: Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression. Biol Psychiatry 2007;62:72-80.
193. Jollant F, Buresi C, Guillaume S, Jaussent I, Bellivier F, Leboyer M, Castelnau D, Malafosse A, Courtet P: The influence of four serotonin-related genes on decision-making in suicide attempters. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:615-624.
194. Yoon HK, Kim YK: TPH2 -703G/T SNP may have important effect on susceptibility to suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:403-409.